Local
Tempus AI (TEM) gets a $200 million AstraZeneca commitment as the two extend their data deal through 2031
A Roundtable is a way to meet new people and discuss this article in person at a local coffee shop or other venue.
Roundtables are designed for groups of four, with a shared subject and room for everyone to speak. Come for discussion, with no dating expectation.
Source: AIStockWire
Key points Tempus AI gets a new five-year AstraZeneca commitment How much AstraZeneca has to spend each year What happens if AstraZeneca spends less How the deal compares with Tempus's data sales AstraZeneca (AZN) has committed $200 million in fees to Tempus AI (TEM) for patient data and AI tools used in cancer research under an amended agreement covering 2027 through 2031. The deal sets a target of $40 million a year, with a $32 million annual minimum. It also includes provisions to extend the agreement and to waive or reduce shortfalls. The amendment pushes the agreement's end date from 2028 to 2031. Tempus shares were at $63.25 at 12:17 p.m. ET on Nov. 18, down 0.3% from the Nov. 17 close of $63.43. What does AstraZeneca have to spend? The amendment, signed Nov. 16 and effective Jan. 1, 2027, covers five years. AstraZeneca's $200 million commitment works out to a $40 million annual target, though the minimum for each year is $32 million.
This excerpt comes from the named source. Read the original for the full reporting.
Read the original at AIStockWire



